Methods for Detection of Biological Substances

Abstract

Methods and compositions are provided for detection of biological substances in nasal specimen.

1 . (canceled) 
     
     
         2 . A method comprising:
 (a) obtaining a saliva specimen from a patient; and   (b) detecting a biological substance or element in said specimen, wherein said biologic substance or element is associated with a disease or condition, and wherein said disease is not a respiratory disease.   
     
     
         3 . The method of  claim 2 , wherein the biological substance comprises agouti related protein, alpha fetoprotein (AFP), brain derived neurotrophic factor (BDNF), bone morphogenetic protein-2 (BMP-2), ciliary neurotrophic factor (CNTF), a cyclic nucleotide, thymus and activation-regulated chemokines (CCL17/TARC) CC chemokines, cystatin, D-dimer, E selectin, endoglin, epidermal growth factor (EGF), endothelial nitric oxide synthase (eNOS), FAS ligand, fibroblastic growth factor basic (FGF basic), granulocyte macrophage colony stimulating factor (GM-CSF), hepatocyte growth factor (HGF), inducible nitric oxide synthase (iNOS), insulin-like growth factor 1 (IGF-1), interferon alpha (INF-.alpha.), interferon beta (INF-.beta.), interferon omega (INF-.omega.), intracellular adhesion molecule 1 (ICAM-1), interleukin-1 receptor (IL-1 receptor), interleukin-2 receptor (IL-2 receptor), interleukin-3 (IL-3), interleukin-15 (IL-15), interleukin-17 (IL-17), interleukin-18 (IL-18), keratinocyte growth factor (KGF), L-selectin, leptin, leukemia inhibitor factor (LIF), matrix metalloproteinase 1 (MVP-1), migrating inhibitory factor (MIF), nerve growth factor (NGF), P selectin, placental growth factor (PlGF), platelet derived growth factor-AA (PDGF-AA), platelet derived growth factor-BB (PDGF-BB), pro-B type natiuretic peptide, receptor for abdominal glycation end product (RAGE), stem cell factor (SCF), substance P, triggering receptor expressed on myeloid cells (TREM-1), transforming growth factor alpha (TGF-.alpha.), transforming growth factor beta (TGF-.beta.), tumor necrosis factor receptor 1(TNF-R1), tumor necrosis factor receptor 2 (TNF-R2), TNF-related apoptosis-inducing ligand (TRAIL), vascular cell adhesion molecule 1 (VCAM1), vascular endothelial growth factor C (VEGF-C), vascular growth factor D (VEGF-D), vascular endothelia growth factor receptor 1 (VEGFR1), or vascular endothelia growth factor receptor 2 (VEGFR2). 
     
     
         4 . The method of  claim 2 , wherein said biological substance is a nucleic acid, a protein, a carbohydrate, a lipid, a metabolite, a hormone, or combinations thereof. 
     
     
         5 . The method of  claim 2 , wherein said biological substance is a protein. 
     
     
         6 . The method of  claim 2 , wherein said detecting is by immunoassay, mass spectrometry, liquid chromatography, electrophoresis, arrays, or biologic sensors. 
     
     
         7 . The method of  claim 2 , wherein said detection of a biological substance or element is performed on a point of care device. 
     
     
         8 . The method of  claim 2 , wherein said element is a metal. 
     
     
         9 . The method of  claim 8 , wherein said metal is copper or zinc. 
     
     
         10 . The method of  claim 2 , wherein said disease or condition is preeclampsia, a bacterial infection, a viral infection, a parasitic infection, a metabolic disease, a gastrointestinal disease, a cardiovascular disease, a neurologic disease, a hematologic disease, an endocrine disease, a malignant disease, an autoimmune disease, or an inflammatory disease. 
     
     
         11 . The method of  claim 10 , further comprising administering a therapeutically effective amount of a drug or active agent to said patient. 
     
     
         12 . The method of  claim 11 , wherein said administering comprises oral administration, transmucosal administration, buccal administration, nasal administration, parental administration, intravenous administration, subcutaneous administration, intramuscular administration, transdermal administration, or rectal administration. 
     
     
         13 . The method of  claim 11 , wherein said administering is by nasal administration. 
     
     
         14 . A method comprising:
 (a) obtaining a saliva specimen from a patient;   (b) detecting a biological substance or element in said specimen, wherein said biologic substance or element is associated with the likelihood of occurrence of a disease or condition, and wherein said disease is not a respiratory disease.   
     
     
         15 . The method of  claim 14 , wherein said biological substance comprises wherein the biological substance comprises agouti related protein, alpha fetoprotein (AFP), brain derived neurotrophic factor (BDNF), bone morphogenetic protein-2 (BMP-2), ciliary neurotrophic factor (CNTF), a cyclic nucleotide, thymus and activation-regulated chemokines (CCL17/TARC) CC chemokines, cystatin, D-dimer, E selectin, endoglin, epidermal growth factor (EGF), endothelial nitric oxide synthase (eNOS), FAS ligand, fibroblastic growth factor basic (FGF basic), granulocyte macrophage colony stimulating factor (GM-CSF), hepatocyte growth factor (HGF), inducible nitric oxide synthase (iNOS), insulin-like growth factor 1 (IGF-1), interferon alpha (INF-.alpha.), interferon beta (INF-.beta.), interferon omega (INF-.omega.), intracellular adhesion molecule 1 (ICAM-1), interleukin-1 receptor (IL-1 receptor), interleukin-2 receptor (IL-2 receptor), interleukin-3 (IL-3), interleukin-15 (IL-15), interleukin-17 (IL-17), interleukin-18 (IL-18), keratinocyte growth factor (KGF), L-selectin, leptin, leukemia inhibitor factor (LIF), matrix metalloproteinase 1 (MVP-1), migrating inhibitory factor (MIF), nerve growth factor (NGF), P selectin, placental growth factor (PlGF), platelet derived growth factor-AA (PDGF-AA), platelet derived growth factor-BB (PDGF-BB), pro-B type natiuretic peptide, receptor for abdominal glycation end product (RAGE), stem cell factor (SCF), substance P, triggering receptor expressed on myeloid cells (TREM-1), transforming growth factor alpha (TGF-.alpha.), transforming growth factor beta (TGF-.beta.), tumor necrosis factor receptor 1(TNF-R1), tumor necrosis factor receptor 2 (TNF-R2), TNF-related apoptosis-inducing ligand (TRAIL), vascular cell adhesion molecule 1 (VCAM1), vascular endothelial growth factor C (VEGF-C), vascular growth factor D (VEGF-D), vascular endothelia growth factor receptor 1 (VEGFR1), or vascular endothelia growth factor receptor 2 (VEGFR2). 
     
     
         16 . The method of  claim 14 , wherein said biological substance is a nucleic acid, a protein, a carbohydrate, a lipid, a metabolite, a hormone, or combinations thereof. 
     
     
         17 . The method of  claim 14 , wherein said biological substance is a protein. 
     
     
         18 . The method of  claim 14 , wherein said detecting is by immunoassay, mass spectrometry, liquid chromatography, electrophoresis, arrays, or biologic sensors. 
     
     
         19 . The method of  claim 14 , wherein said element is a metal. 
     
     
         20 . The method of  claim 19 , wherein said metal is copper or zinc. 
     
     
         21 . The method of  claim 14 , wherein said detection of a biological substance or element is performed on a point of care device.